Synthesis of phthalimido-desmuramylpeptide analogues as potential immunomodulating agents. 1995

U Urleb, and A Krbavcic, and M Sollner, and D Kikelj, and S Pecar
Department of Pharmacy, University of Ljubljana, Slovenia.

The preparation of immunologically active phthalimido desmuramylpeptide analogues 2e-h, 4c-d, and 7b is described. The N-acetylmuramic acid in the muramyl dipeptide has been replaced by a phthaloylated acyclic moiety such as N-phthaloylated amino acids 1a-c, 2-(2-phthalimidoethoxy)acetic acid 3, or by the carbocyclic rac. trans-2-(2'-phthalimidocyclohexyloxy)acetic acid 6.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D010797 Phthalimides The imide of phthalic acids.
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

U Urleb, and A Krbavcic, and M Sollner, and D Kikelj, and S Pecar
December 2006, Bioorganic & medicinal chemistry,
U Urleb, and A Krbavcic, and M Sollner, and D Kikelj, and S Pecar
October 2007, Bioorganic & medicinal chemistry,
U Urleb, and A Krbavcic, and M Sollner, and D Kikelj, and S Pecar
September 2014, The Journal of steroid biochemistry and molecular biology,
U Urleb, and A Krbavcic, and M Sollner, and D Kikelj, and S Pecar
August 2000, Archives of pharmacal research,
U Urleb, and A Krbavcic, and M Sollner, and D Kikelj, and S Pecar
January 2004, Archiv der Pharmazie,
U Urleb, and A Krbavcic, and M Sollner, and D Kikelj, and S Pecar
April 2006, Bioorganic & medicinal chemistry letters,
U Urleb, and A Krbavcic, and M Sollner, and D Kikelj, and S Pecar
February 2022, Marine drugs,
U Urleb, and A Krbavcic, and M Sollner, and D Kikelj, and S Pecar
September 2003, Bioorganic & medicinal chemistry,
U Urleb, and A Krbavcic, and M Sollner, and D Kikelj, and S Pecar
January 1968, Journal of the Chemical Society. Perkin transactions 1,
U Urleb, and A Krbavcic, and M Sollner, and D Kikelj, and S Pecar
April 2009, Tetrahedron letters,
Copied contents to your clipboard!